Single Tracer Versus Dual Tracer Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Breast Cancer : A Comparative Study
NCT07932574, Not applicable, Completed, King Edward Medical University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Single Tracer Versus Dual Tracer Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Breast Cancer : A Comparative Study | ClinicalTrials.gov |
| NCT number | NCT07932574 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 110 participants, actual | ClinicalTrials.gov |
| Lead sponsor | King Edward Medical University | ClinicalTrials.gov |
| Conditions | Breast Neoplasm | ClinicalTrials.gov |
| Interventions | single tracer sentinel lymph node biopsy, Dual Tracr Sentinel lymph node biopsy | ClinicalTrials.gov |
| First posted | 2026-11-12 | ClinicalTrials.gov |
| Last updated | 2026-11-12 | ClinicalTrials.gov |
Registered outcomes 5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Sentinel Lymph Node Identification Rate:It will be defined as the proportion of patients in whom at least one sentinel lymph node is successfully identified during surgery using either single tracer or dual tracer technique. | peri operatively at the time of sentinel lymph node biopsy , following administration of the allocated single or dual tracer technique | Sentinel Lymph Node Identification Rate:It will be defined as the proportion of patients in whom at least one sentinel lymph node is successfully identified during surgery using either single tracer or dual tracer technique.Identification rate will be calculated as:This outcome will be compared between the single tracer group and dual tracer group. | ClinicalTrials.gov |
| Secondary | false negative rate of sentinel lymph node biopsy | within 10 days after surgery, following availability of final histopathological results of completion axillary lymph node dissection specimens | False negative rate will be defined as the proportion of patients in whom sentinel lymph node biopsy is negative but axillary lymph node dissection reveals metastatic lymph nodes. | ClinicalTrials.gov |
| Secondary | Number of Sentinel Lymph Nodes: | with in 1 hrs after histopathology Report of sentinel lymph node biopsy recieved | Number of sentinel lymph nodes Retrieved The total number of sentinel lymph nodes removed during surgery will be recorded and compared between the single tracer and dual tracer groups | ClinicalTrials.gov |
| Secondary | Operative Time: | From the start of surgical procedure to completion of procedure measured intraoperativley and recorded in minutes | The time required to identify and retrieve sentinel lymph nodes will be recorded and compared between both groups. | ClinicalTrials.gov |
| Other | Incidence of Procedure-Related Complications | From the time of surgery until 30 days postoperatively. | The proportion of patients experiencing procedure-related complications, including allergic reactions to the tracer or dye, seroma, surgical site infection, and lymphoedema, will be assessed and compared between the single-tracer and dual-tracer groups. Results will be reported as the number and percentage of patients experiencing each complication. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)